145 related articles for article (PubMed ID: 1449024)
1. Comparison of cellular phenotypes in tumor cyst and ascitic fluid from ovarian serous carcinoma.
Harlozinska A; Bar JK; Richter R; Cislo M
Acta Cytol; 1992; 36(6):869-74. PubMed ID: 1449024
[TBL] [Abstract][Full Text] [Related]
2. Density distribution and immunological reactivity of tumor cells from peritoneal effusions of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Cisło M; Richter R; Rabczyński J
Anal Cell Pathol; 1992 Jan; 4(1):1-12. PubMed ID: 1370907
[TBL] [Abstract][Full Text] [Related]
3. Density distribution and antigenic characterization of cell subpopulations isolated from cystic fluids of ovarian serous neoplasms.
Harłozińska A; Bar JK; Rabczyński J; Noworolska A; Richter R; Cisło M
Anticancer Res; 1989; 9(1):161-6. PubMed ID: 2705745
[TBL] [Abstract][Full Text] [Related]
4. Density distribution, cytomorphologic features and immunologic characteristics of ovarian and endometrial clear cell carcinomas.
Harłozińska A; Rabczyński J; Bar JK; Richter R
Acta Cytol; 1990; 34(5):657-63. PubMed ID: 2220244
[TBL] [Abstract][Full Text] [Related]
5. Morphological and immunological heterogeneity of human ovarian neoplasms.
Harłozińska A; Rabczyński J; Bar JK; Richter R
Arch Immunol Ther Exp (Warsz); 1991; 39(4):419-29. PubMed ID: 1821619
[TBL] [Abstract][Full Text] [Related]
6. Cellular heterogeneity in human ovarian carcinoma studied by density gradient fractionation.
Mackillop WJ; Buick RN
Stem Cells (1981); 1982; 1(6):355-66. PubMed ID: 7147093
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody against human ovarian tumor-associated antigens.
Poels LG; Peters D; van Megen Y; Vooijs GP; Verheyen RN; Willemen A; van Niekerk CC; Jap PH; Mungyer G; Kenemans P
J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452
[TBL] [Abstract][Full Text] [Related]
9. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro.
Pattillo RA; Story MT; Ruckert AC
Cancer Res; 1979 Apr; 39(4):1185-92. PubMed ID: 421202
[TBL] [Abstract][Full Text] [Related]
10. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
Rao GS; Hanjani P
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
13. [Detection of cancer cells in peritoneal fluid or washing by immunocytochemical staining with monoclonal antibodies].
Zhao Y
Zhonghua Fu Chan Ke Za Zhi; 1992 May; 27(3):159-61, 189. PubMed ID: 1382925
[TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
[TBL] [Abstract][Full Text] [Related]
15. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites.
Barker SD; Casado E; Gomez-Navarro J; Xiang J; Arafat W; Mahasreshti P; Pustilnik TB; Hemminki A; Siegal GP; Alvarez RD; Curiel DT
Gynecol Oncol; 2001 Jul; 82(1):57-63. PubMed ID: 11426962
[TBL] [Abstract][Full Text] [Related]
16. CA 125 and carcinoembryonic antigen levels in cyst fluid, ascites and serum of patients with ovarian neoplasms.
Harłozińska A; Bar JK; Gawlikowski W; Richter R; Cisło M
Ann Chir Gynaecol; 1991; 80(4):368-75. PubMed ID: 1667567
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
[TBL] [Abstract][Full Text] [Related]
18. Tumor associated antigen in ovarian carcinoma.
Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
[TBL] [Abstract][Full Text] [Related]
19. Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH-1).
Bar JK; Harlozińska A
Anticancer Res; 2000; 20(5A):2975-80. PubMed ID: 11062710
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes.
Melioli G; Ferrari I; Casartelli G; Ragni N
Gynecol Oncol; 1993 Mar; 48(3):301-7. PubMed ID: 8462898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
